Synthesis and Antibacterial Evaluation of Clarithromycin Derivatives
Antibiotics · 19.11.2026 · 15 (11) · 1156
DOI: 10.3390/antibiotics15111156 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibiotics, online erschienen am 19.11.2026. Verfasst von Nadine M. Qalalweh und 4 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Clarithromycin is a common macrolide antibiotic used to treat bacterial infections, but it can be less effective in clinical settings due to its high level of antibiotic resistance and the bitter taste which makes it less palatable to the patient and thus less effective for compliance. The aim of present study was to synthesize and characterize five new derivatives of clarithromycin and check their antibacterial activity and hydrolytic stability to explore the possibility of modifying clarithromycin as an antibacterial agent and/or as a prodrug.
Methods
Rational modification of the structure has been used to synthesize five clarithromycin derivatives and characterized by spectroscopic methods. They were assessed for hydrolytic stability at acidic, mildly acidic and physiological pH (pH 2.2, 5.5 and 7.4). The antibacterial activity was measured in the minimum inhibitory concentration (MIC) and half-maximal inhibitory concentration (IC50) against Streptococcus pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus and Escherichia coli.
Results
All of our synthesized derivatives showed antibacterial activity which is species dependent. Derivatives exhibited increased activity against P. aeruginosa when compared to clarithromycin. Of the compounds synthesized, Compound 3 (clarithromycin + 3,5-dinitrobenzoyl chloride) exhibited enhanced activity against all four bacterial species. It was active against S. pneumoniae, P. aeruginosa and S. aureus with IC50 values of 0.27 ± 0.03 µg/mL, 0.32 ± 0.22 µg/mL and 0.15 ± 0.04 µg/mL respectively, and some activity against E. coli. Studies of hydrolysis demonstrated that Compound 3 was not observed to regenerate Clarithromycin under the conditions studied, suggesting that it is not a standard prodrug of Clarithromycin.
Conclusions
Clarithromycin derivatives with modified antibacterial activities and increased activity against P. aeruginosa were created by structural modification. Instead of regenerating clarithromycin, Compound 3’s antibacterial activity might be linked to the altered molecule and/or its hydrolysis products. These results encourage additional in vivo, pharmacological, and mechanistic research on this derivative.
Zitieren
APA
Qalalweh, N. M., Al-Najjar, B. O., Hijaz, H. A., Qalalweh, H., & Houshia, O. (2026). Synthesis and Antibacterial Evaluation of Clarithromycin Derivatives. Antibiotics, 15(11), 1156. https://doi.org/10.3390/antibiotics15111156
Vancouver
Qalalweh NM, Al-Najjar BO, Hijaz HA, Qalalweh H, Houshia O. Synthesis and Antibacterial Evaluation of Clarithromycin Derivatives. Antibiotics. 2026;15(11):1156. doi:10.3390/antibiotics15111156
BibTeX
@article{Qalalweh2026,
author = {Qalalweh, Nadine M. and Al-Najjar, Belal O. and Hijaz, Hatem A. and Qalalweh, Haneen and Houshia, Orwah},
title = {Synthesis and Antibacterial Evaluation of Clarithromycin Derivatives},
journal = {Antibiotics},
year = {2026},
volume = {15},
number = {11},
pages = {1156},
doi = {10.3390/antibiotics15111156}
}
EUVIMED